Affiliation: Stanford University
- Natural killer cells: can they be useful as adoptive immunotherapy for cancer?Sally Arai
Stanford University Medical Center, Division of Bone Marrow Transplant, 300 Pasteur Drive, H3249, MC 5623, Stanford, CA 94305, USA
Expert Opin Biol Ther 5:163-72. 2005..This review discusses the recent knowledge on NK cell biology that has impacted on its development as a treatment for cancer...
- Rituximab in hematopoietic cell transplantationSally Arai
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University Medical Center, H3249, Stanford, CA 94305, USA
Expert Opin Biol Ther 10:971-82. 2010..The success of rituximab therapy in managing B cell malignancies supports its widespread application in both autologous and allogeneic hematopoietic cell transplantation...
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphomaSally Arai
Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
Biol Blood Marrow Transplant 16:1145-54. 2010..This new transplant regimen for HL resulted in decreased BCNU toxicity with encouraging FFP and OS. A prospective, risk-modeled comparison of this new combination with other conditioning regimens is warranted...
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trialS Arai
Rush University Medical Center, Chicago, Illinois, USA
Cytotherapy 10:625-32. 2008....
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidenceSally Arai
Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA 94305, USA
Blood 119:6145-54. 2012..01). Overall survival and freedom from progression at 4 years for chronic lymphocytic leukemia patients were 73% and 47%, respectively; for mantle-cell lymphoma patients, they were 69% and 53%, respectively...
- TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donorsHolbrook E Kohrt
Department of Medicine, Stanford University School of Medicine, CA 94305, USA
Blood 114:1099-109. 2009..Active trial registration currently at clinicaltrials.gov under IDs of NCT00185640 and NCT00186615...
- The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosisShira Dinner
Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA
Br J Haematol 161:367-72. 2013..Evaluation of bone marrow plasma cell infiltration and presence of myeloma associated end organ damage could be clinically useful for prognostication of patients with AL...
- Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantationGinna G Laport
Division of Blood and Marrow Transplantation, Stanford University School of Medicine, 300 Pastaur Drive, Stanford, CA 94305, USA
Biol Blood Marrow Transplant 17:1679-87. 2011....
- A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodiesGeorge L Chen
Department of Medicine Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, CA, USA
Blood 118:4070-8. 2011..We conclude that cGVHD responds to imatinib through multiple pathways that may include PDGFRA signal transduction. This study is registered at www.clinicaltrials.gov as #NCT00760981...
- Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD ConsortiumDavid A Jacobsohn
Division of Blood and Marrow Transplantation, Children s National Medical Center, Washington, DC, USA
Blood 120:2545-52; quiz 2774. 2012....
- Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levelsJakub Tolar
Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Biol Blood Marrow Transplant 18:1007-11. 2012..CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m(2)), and antithymocyte globulin was associated with excessive organ toxicity...
- Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimenJoanna M Schaenman
Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305 5623, USA
Biol Blood Marrow Transplant 17:693-702. 2011..These observations demonstrate the dynamic nature of immunity in relation to CMV antigen exposure in the complex environment resulting from NMA conditions where both donor and residual recipient immune response affect viral control...
- H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host diseaseBita Sahaf
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
Proc Natl Acad Sci U S A 110:3005-10. 2013..Our study suggests that detection of anti-DBY-2 B cells may predict cGVHD and that this prediction may have clinical utility. Validation of this hypothesis will require larger prospective studies...
- Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host diseaseJoshua Melson
Department of Gastroenterology, Rush University Medical Center, Chicago, Illinois, USA
Am J Hematol 82:881-6. 2007..Crypt loss is a histological finding in acute gastrointestinal Graft-Versus-Host Disease (GI-GvHD) of undefined clinical significance...
- Hematopoietic stem cell transplantation: bone marrow vs. mobilized peripheral bloodSally Arai
Section of Bone Marrow Transplant and Cell Therapy, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60012, USA
Arch Med Res 34:545-53. 2003..PBSCT and will be reviewed. In addition, comparisons between the two stem cell sources in unrelated donor transplantation and the increasingly utilized nonmyeloablative transplantation will be discussed...
- Role of immunotherapy in stem cell transplantationSally Arai
Section of Bone Marrow Transplant and Cell Therapy, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
Int J Hematol 77:22-8. 2003..It remains to be seen if such novel cellular therapies can also be implemented after autologous transplantation via the use of engineered allogeneic immune cells...
- Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus CriteriaSally Arai
Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA
Blood 118:4242-9. 2011..Patients with mild chronic GVHD have a good prognosis, while patients with severe chronic GVHD have a poor prognosis. This study was registered at www.clinicaltrials.gov as no. NCT00637689...
- Successful surgical and medical treatment of rhizopus osteomyelitis following hematopoietic cell transplantationNikita Vashi
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University Medical Center, Stanford, California 94305, USA
Orthopedics 35:e1556-61. 2012....
- Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategiesBrandon C Varr
Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA, USA
J Heart Lung Transplant 31:325-31. 2012..A novel strategy of OHT, followed by light-chain suppressive chemotherapy before autologous hematopoietic stem cell transplant, is feasible for patients with light-chain amyloidosis...
- A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancerAllison W Kurian
Department of Medicine, Division of Oncology, and the Veterans Affairs Palo Alto Health Care System and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA
J Clin Oncol 25:634-41. 2007..We sought to evaluate the cost effectiveness of these regimens, which are expensive and potentially toxic...
- Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcomePaul G Richardson
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 100:4337-43. 2002..Certain features associated with successful outcome may correlate with DF-related treatment effects, and prospective evaluation of DF therapy for severe VOD should allow better definition of predictors of response or failure...
- Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatmentSally Arai
Johns Hopkins Oncology Center, Baltimore, Maryland, USA
Biol Blood Marrow Transplant 8:155-60. 2002..Patients with steroid-refractory GVHD should be enrolled in clinical study until there are data to support a standard salvage therapy...
- GVHD and Relapse:Ex-Vivo Expanded Allogeneic TherapySally Arai; Fiscal Year: 2007..Well designed study of this novel adoptive cellular approach with NK-92 has the potential to substantially improve the outcome of allogeneic SCT and is the goal of a 5-year career development program in clinical research. ..